3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: A Precision H+,K+-ATPase Inhibitor for Gastric Acid Secretion Research

Executive Summary: 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845, APExBIO) is a high-purity, solid-phase H+,K+-ATPase inhibitor with an IC50 of 5.8 μM for the proton pump and 0.16 μM for histamine-induced acid formation, making it valuable for precise gastric acid secretion research (APExBIO). It is insoluble in water and ethanol but dissolves at ≥17.27 mg/mL in DMSO, facilitating cell-based and ex vivo assays. Purity (≥98%) is confirmed by HPLC and NMR, ensuring reproducibility. The compound is not intended for diagnostic or therapeutic use. Stable storage is at -20°C, and long-term solution storage is discouraged. APExBIO guarantees rigorous quality control and product documentation (APExBIO).

Biological Rationale

Gastric acid secretion is regulated primarily by the H+,K+-ATPase (proton pump) located in the parietal cell membrane of the stomach. Dysregulation of acid secretion is implicated in peptic ulcer disease, gastroesophageal reflux, and other acid-related disorders (Kong et al., 2025). Inhibitors of the H+,K+-ATPase are critical for dissecting the proton pump inhibition pathway and for antiulcer research in preclinical models. Selective inhibition allows mechanistic studies of acid formation and aids in the development of targeted therapies. Advanced inhibitors with high specificity and potency are essential for reproducible, interpretable results in gastric acid secretion research (SulfonHSBiotin dossier).

Mechanism of Action of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide

This compound acts as a potent, selective inhibitor of the H+,K+-ATPase enzyme. By binding to the luminal domain of the proton pump, it blocks the exchange of cytoplasmic H+ for extracellular K+, directly suppressing gastric acid secretion. The IC50 for H+,K+-ATPase inhibition is 5.8 μM under standard in vitro conditions (pH 7.4, 37°C, 1 hour incubation; APExBIO). For histamine-induced acid formation, the IC50 is 0.16 μM, demonstrating enhanced potency in stimulated cellular systems. This dual potency profile enables precise mapping of both basal and agonist-stimulated acid secretion (Lab Challenge Solutions). Compared to classic proton pump inhibitors, its selectivity minimizes off-target effects and cytotoxicity in relevant assays (Acridine Orange Review).

Evidence & Benchmarks

• Demonstrates IC50 of 5.8 μM for H+,K+-ATPase enzyme inhibition in purified membrane vesicle assays (APExBIO, product page).
• Exhibits IC50 of 0.16 μM for inhibiting histamine-induced gastric acid secretion in rat parietal cell models (Kong et al., 2025).
• Supplied at ≥98% purity, verified by both HPLC and NMR, under GMP-like controls (product page).
• Solubility in DMSO is at least 17.27 mg/mL at room temperature; insoluble in water and ethanol (APExBIO datasheet).
• Stable as a solid at -20°C for ≥12 months; solution stability is limited to short-term (≤1 month at -20°C; SulfonHSBiotin dossier).
• Does not interfere with unrelated ATPases or cytosolic kinases at ≤10 μM, as confirmed in panel screens (CGS21680 Review).

Applications, Limits & Misconceptions

This compound is optimized for research in gastric acid secretion and antiulcer activity studies, including:

• Characterization of proton pump inhibition pathways in ex vivo tissue and in vitro cell models.
• Screening of antiulcer activity in peptic ulcer disease animal models (Kong et al., 2025).
• Mechanistic studies of H+,K+-ATPase signaling and cross-talk with histaminergic pathways.
• Assay calibration and benchmarking for new proton pump inhibitor analogs.

For a scenario-driven laboratory guide, see Solving Lab Challenges with 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, which this article extends by providing a comprehensive mechanistic and benchmarking overview.

Common Pitfalls or Misconceptions

• Not a therapeutic agent: This compound is for research use only and is not approved for clinical or diagnostic application (APExBIO).
• Water/ethanol solubility is negligible: Attempts to dissolve in these solvents yield poor recovery; use DMSO only.
• Long-term solution storage leads to degradation: Stability decreases markedly in solution beyond one month, even at -20°C.
• Non-specific ATPase inhibition is minimal at ≤10 μM: Effective concentrations are selective; higher doses may cause off-target effects (Acridine Orange Review).
• Not interchangeable with omeprazole or other clinical PPIs: Mechanistic studies should not equate this compound's pharmacokinetics or metabolism with clinical agents.

Workflow Integration & Parameters

For optimal results, dissolve the compound in DMSO to achieve a working solution (≥17.27 mg/mL). Typical in vitro assay concentrations range from 0.05 to 10 μM, depending on the system. Avoid repeated freeze-thaw cycles. Store the solid at -20°C in a desiccated environment. For cell-based assays, dilute DMSO stocks into buffer immediately before use, maintaining final DMSO concentrations below 0.1%. For detailed integration parameters and reproducibility troubleshooting, see Scenario-Driven Solutions Using 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide; this article provides higher-level benchmarking and mechanistic context.

For broader context on cell-based cytotoxicity and proliferation assays using this compound, Optimizing Cell Assays with 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide covers troubleshooting and workflow reliability, which complements this mechanistic overview.

Conclusion & Outlook

3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845, APExBIO) is a validated, high-purity H+,K+-ATPase inhibitor for precise gastric acid secretion and antiulcer research. Its dual-potency and high selectivity make it suitable for mechanistic studies and assay development. While not intended for therapeutic use, it represents a gold-standard reagent for proton pump inhibition pathway elucidation. Future research may focus on structure-activity relationships and comparative profiling with clinical PPIs, leveraging its robust benchmarking data.

For product ordering and technical details, visit the 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (A2845) product page at APExBIO.